AJP - Endo Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Endocrinol Metab 284: E841-E854, 2003. First published December 10, 2002; doi:10.1152/ajpendo.00348.2002
0193-1849/03 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
284/4/E841    most recent
00348.2002v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (37)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brand, C. L.
Right arrow Articles by Wassermann, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brand, C. L.
Right arrow Articles by Wassermann, K.
Vol. 284, Issue 4, E841-E854, April 2003

Dual PPARalpha /gamma activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats

Christian L. Brand1, Jeppe Sturis1, Carsten F. Gotfredsen1, Jan Fleckner1, Christian Fledelius1, Bo F. Hansen1, Birgitte Andersen1, Ji-Ming Ye2, Per Sauerberg1, and Karsten Wassermann1

1 Research and Development, Novo Nordisk, DK-2880 Bagsvaerd, Denmark; and 2 Garvan Institute of Medical Research, Darlinghurst, Sydney 2010, Australia

Improvement of insulin sensitivity and lipid and glucose metabolism by coactivation of both nuclear peroxisome proliferator-activated receptor (PPAR)gamma and PPARalpha potentially provides beneficial effects over existing PPARgamma and alpha  preferential drugs, respectively, in treatment of type 2 diabetes. We examined the effects of the dual PPARalpha /gamma agonist ragaglitazar on hyperglycemia and whole body insulin sensitivity in early and late diabetes stages in Zucker diabetic fatty (ZDF) rats and compared them with treatment with the PPARgamma preferential agonist rosiglitazone. Despite normalization of hyperglycemia and Hb A1c and reduction of plasma triglycerides by both compounds in both prevention and early intervention studies, ragaglitazar treatment resulted in overall reduced circulating insulin and improved insulin sensitivity to a greater extent than after treatment with rosiglitazone. In late-intervention therapy, ragaglitazar reduced Hb A1c by 2.3% compared with 1.1% by rosiglitazone. Improvement of insulin sensitivity caused by the dual PPARalpha /gamma agonist ragaglitazar seemed to have beneficial impact over that of the PPARgamma -preferential activator rosiglitazone on glycemic control in frankly diabetic ZDF rats.

euglycemic clamp; peroxisome proliferator-activated receptor; ragaglitazar; rosiglitazone; type 2 diabetes; Zucker diabetic fatty


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
Z. Szocs, B. Brunmair, K. Stadlbauer, P. Nowotny, L. Bauer, A. Luger, and C. Furnsinn
Age-Dependent Development of Metabolic Derangement and Effects of Intervention with Pioglitazone in Zucker Diabetic Fatty Rats
J. Pharmacol. Exp. Ther., July 1, 2008; 326(1): 323 - 329.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
B. Chopra, J. Hinley, M. B. Oleksiewicz, and J. Southgate
Trans-Species Comparison of PPAR and RXR Expression by Rat and Human Urothelial Tissues
Toxicol Pathol, April 1, 2008; 36(3): 485 - 495.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
V. Y. Ng, Y. Huang, L. M. Reddy, J. R. Falck, E. T. Lin, and D. L. Kroetz
Cytochrome P450 Eicosanoids are Activators of Peroxisome Proliferator-Activated Receptor {alpha}
Drug Metab. Dispos., July 1, 2007; 35(7): 1126 - 1134.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
A. C. Calkin, S. Giunti, K. A. Jandeleit-Dahm, T. J. Allen, M. E. Cooper, and M. C. Thomas
PPAR-{alpha} and -{gamma} agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse
Nephrol. Dial. Transplant., September 1, 2006; 21(9): 2399 - 2405.
[Abstract] [Full Text] [PDF]

Home page
 Adv. Physiol. Educ.Home page
M. A. Valasek and J. J. Repa
The power of real-time PCR
Advan Physiol Educ, September 1, 2005; 29(3): 151 - 159.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
M. B. Oleksiewicz, I. Thorup, H. S. Nielsen, H. V. Andersen, A. C. Hegelund, L. Iversen, T. S. Guldberg, P. R. Brinck, I. Sjogren, U. K. Thinggaard, et al.
Generalized Cellular Hypertrophy is Induced by a Dual-Acting PPAR Agonist in Rat Urinary Bladder Urothelium In Vivo
Toxicol Pathol, August 1, 2005; 33(5): 552 - 560.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
J. A. Wagner, P. J. Larson, S. Weiss, J. L. Miller, T. W. Doebber, M. S. Wu, D. E. Moller, and K. M. Gottesdiener
Individual and Combined Effects of Peroxisome Proliferator-Activated Receptor and {gamma} Agonists, Fenofibrate and Rosiglitazone, on Biomarkers of Lipid and Glucose Metabolism in Healthy Nondiabetic Volunteers
J. Clin. Pharmacol., May 1, 2005; 45(5): 504 - 513.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
R. Pold, L. S. Jensen, N. Jessen, E. S. Buhl, O. Schmitz, A. Flyvbjerg, N. Fujii, L. J. Goodyear, C. F. Gotfredsen, C. L. Brand, et al.
Long-Term AICAR Administration and Exercise Prevents Diabetes in ZDF Rats
Diabetes, April 1, 2005; 54(4): 928 - 934.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
M. F. Saad, S. Greco, K. Osei, A. J. Lewin, C. Edwards, M. Nunez, and R. R. Reinhardt
Ragaglitazar Improves Glycemic Control and Lipid Profile in Type 2 Diabetic Subjects: A 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm
Diabetes Care, June 1, 2004; 27(6): 1324 - 1329.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
B. K. Skrumsager, K. K. Nielsen, M. Muller, G. Pabst, P. G. Drake, and B. Edsberg
Ragaglitazar: The Pharmacokinetics, Pharmacodynamics, and Tolerability of a Novel Dual PPAR{alpha} and {gamma} Agonist in Healthy Subjects and Patients with Type 2 Diabetes
J. Clin. Pharmacol., November 1, 2003; 43(11): 1244 - 1256.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online